The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation

J. Levitsky; R. N. Formica; R. D. Bloom; M. Charlton; M. Curry; J. Friedewald; J. Friedman; D. Goldberg; S. Hall; M. Ison; T. Kaiser; D. Klassen; G. Klintmalm; J. Kobashigawa; A. Liapakis; K. O'Conner; P. Reese; D. Stewart; N. Terrault; N. Theodoropoulos; J. Trotter; E. Verna; M. Volk

doi:10.1111/ajt.14381

The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation

J. Levitsky^*, R. N. Formica, R. D. Bloom, M. Charlton, M. Curry, J. Friedewald, J. Friedman, D. Goldberg, S. Hall, M. Ison, T. Kaiser, D. Klassen, G. Klintmalm, J. Kobashigawa, A. Liapakis, K. O'Conner, P. Reese, D. Stewart, N. Terrault, N. TheodoropoulosJ. Trotter, E. Verna, M. Volk

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

270 Scopus citations

Abstract

The availability of direct-acting antiviral agents for the treatment of hepatitis C virus (HCV) infection has resulted in a profound shift in the approach to the management of this infection. These changes have affected the practice of solid organ transplantation by altering the framework by which patients with end-stage organ disease are managed and receive organ transplants. The high level of safety and efficacy of these medications in patients with chronic HCV infection provides the opportunity to explore their use in the setting of transplanting organs from HCV-viremic patients into non–HCV-viremic recipients. Because these organs are frequently discarded and typically come from younger donors, this approach has the potential to save lives on the solid organ transplant waitlist. Therefore, an urgent need exists for prospective research protocols that study the risk versus benefit of using organs for hepatitis C–infected donors. In response to this rapidly changing practice and the need for scientific study and consensus, the American Society of Transplantation convened a meeting of experts to review current data and develop the framework for the study of using HCV viremic organs in solid organ transplantation.

Original language	English (US)
Pages (from-to)	2790-2802
Number of pages	13
Journal	American Journal of Transplantation
Volume	17
Issue number	11
DOIs	https://doi.org/10.1111/ajt.14381
State	Published - Nov 2017

Funding

R.B.: consultant, Abbvie, Advisor, Merck. M.C.: consultant, Gilead Sciences, Bristol-Myers Squibb, and AbbVie; grant support from Gilead Sciences, Mallinkrodt, and Conatus. S.H.: speakers bureau, Novartis, CareDx; consultant: St Jude, Abiomed. R.F.: consultant, Genentech. G.K.: principal investigator for a Novartis Sponsored Research Liver Study. J.L.: advisor and stockholder for Transplant Genomics Incorporated; speaker: Gilead, Salix, Novartis; research grants from Novartis, Abbvie; councilor-at-large for the American Society of Transplantation; councilor for the International Liver Transplantation Society. J.K.: grant support and consultant, Novartis; grant support and speakers bureau, Caredx, Inc.; grant support, advisory board, speakers bureau, Caredx; grant support, Alexion. A.M.L.: financial-advisory board, Gilead; past advisory board, Jans-sen; primary investigator, Merck Trials; external advisor on project sponsored by Merck grant; Service-Donate Life Connecticut, American Liver Foundation (no payment for these). P.R.: research support to University of Pennsylvania from Merck to support research on transplantation using HCV organs; participation in Merck-organized meetings (including meals) related to transplantation using HCV organs; research support to University of Pennsylvania from CVS Caremark to support research on medication adherence; research support to University of Pennsylvania from Astra-Zeneca/Bristol-Myers Squibb to support research related to renal outcomes for Saxagliptin users; consulting with COHRDATA on epidemiology of medications to control dialysis and phosphorus among dialysis patients; associate editor for the American Journal of Kidney Diseases. N.T.: Gilead, grant support/consultant; Bristol-Myers Squibb, grant support; Biotest, grant support/consultant; Abbvie, grant support; Merck, grant support/consultant; UpToDate, royalty; CCO Hepatitis Educational Material Development; Practice Point Communications Continuing Medical Education; Focus Medical Communications Continuing Medical Education; Annen-berg Center for Health Sciences Continuing Medical Education; PRIME Continuing Medical Education; Mylan Pharmaceuticals, consultant. N.T.: research grant funding from Mendez National Institute of Transplantation Foundation (nonprofit), member of OPTN, DTAC committee, member of AST ID COP executive committee. J.T.: Gilead speakers bureau. E.V.: grant support from Salix. M.V.: clinical consultations from Best Doctors. The other remaining authors report no conflicts of interest to disclose as described by the American Journal of Transplantation.

Keywords

clinical decision-making
clinical research/practice
clinical trial design
donors and donation: donor-derived infections
education
infection and infectious agents
organ allocation
organ procurement and allocation
organ transplantation in general
viral: hepatitis C

ASJC Scopus subject areas

Transplantation
Pharmacology (medical)
Immunology and Allergy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/ajt.14381

Cite this

Levitsky, J., Formica, R. N., Bloom, R. D., Charlton, M., Curry, M., Friedewald, J., Friedman, J., Goldberg, D., Hall, S., Ison, M., Kaiser, T., Klassen, D., Klintmalm, G., Kobashigawa, J., Liapakis, A., O'Conner, K., Reese, P., Stewart, D., Terrault, N., ... Volk, M. (2017). The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. American Journal of Transplantation, 17(11), 2790-2802. https://doi.org/10.1111/ajt.14381

@article{f59832005e3c4e119ad7690105ae5151,

title = "The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation",

abstract = "The availability of direct-acting antiviral agents for the treatment of hepatitis C virus (HCV) infection has resulted in a profound shift in the approach to the management of this infection. These changes have affected the practice of solid organ transplantation by altering the framework by which patients with end-stage organ disease are managed and receive organ transplants. The high level of safety and efficacy of these medications in patients with chronic HCV infection provides the opportunity to explore their use in the setting of transplanting organs from HCV-viremic patients into non–HCV-viremic recipients. Because these organs are frequently discarded and typically come from younger donors, this approach has the potential to save lives on the solid organ transplant waitlist. Therefore, an urgent need exists for prospective research protocols that study the risk versus benefit of using organs for hepatitis C–infected donors. In response to this rapidly changing practice and the need for scientific study and consensus, the American Society of Transplantation convened a meeting of experts to review current data and develop the framework for the study of using HCV viremic organs in solid organ transplantation.",

keywords = "clinical decision-making, clinical research/practice, clinical trial design, donors and donation: donor-derived infections, education, infection and infectious agents, organ allocation, organ procurement and allocation, organ transplantation in general, viral: hepatitis C",

author = "J. Levitsky and Formica, {R. N.} and Bloom, {R. D.} and M. Charlton and M. Curry and J. Friedewald and J. Friedman and D. Goldberg and S. Hall and M. Ison and T. Kaiser and D. Klassen and G. Klintmalm and J. Kobashigawa and A. Liapakis and K. O'Conner and P. Reese and D. Stewart and N. Terrault and N. Theodoropoulos and J. Trotter and E. Verna and M. Volk",

note = "Publisher Copyright: {\textcopyright} 2017 The American Society of Transplantation and the American Society of Transplant Surgeons",

year = "2017",

month = nov,

doi = "10.1111/ajt.14381",

language = "English (US)",

volume = "17",

pages = "2790--2802",

journal = "American Journal of Transplantation",

issn = "1600-6135",

publisher = "Wiley-Blackwell",

number = "11",

}

Levitsky, J, Formica, RN, Bloom, RD, Charlton, M, Curry, M, Friedewald, J, Friedman, J, Goldberg, D, Hall, S, Ison, M, Kaiser, T, Klassen, D, Klintmalm, G, Kobashigawa, J, Liapakis, A, O'Conner, K, Reese, P, Stewart, D, Terrault, N, Theodoropoulos, N, Trotter, J, Verna, E & Volk, M 2017, 'The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation', American Journal of Transplantation, vol. 17, no. 11, pp. 2790-2802. https://doi.org/10.1111/ajt.14381

TY - JOUR

T1 - The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation

AU - Levitsky, J.

AU - Formica, R. N.

AU - Bloom, R. D.

AU - Charlton, M.

AU - Curry, M.

AU - Friedewald, J.

AU - Friedman, J.

AU - Goldberg, D.

AU - Hall, S.

AU - Ison, M.

AU - Kaiser, T.

AU - Klassen, D.

AU - Klintmalm, G.

AU - Kobashigawa, J.

AU - Liapakis, A.

AU - O'Conner, K.

AU - Reese, P.

AU - Stewart, D.

AU - Terrault, N.

AU - Theodoropoulos, N.

AU - Trotter, J.

AU - Verna, E.

AU - Volk, M.

PY - 2017/11

Y1 - 2017/11

N2 - The availability of direct-acting antiviral agents for the treatment of hepatitis C virus (HCV) infection has resulted in a profound shift in the approach to the management of this infection. These changes have affected the practice of solid organ transplantation by altering the framework by which patients with end-stage organ disease are managed and receive organ transplants. The high level of safety and efficacy of these medications in patients with chronic HCV infection provides the opportunity to explore their use in the setting of transplanting organs from HCV-viremic patients into non–HCV-viremic recipients. Because these organs are frequently discarded and typically come from younger donors, this approach has the potential to save lives on the solid organ transplant waitlist. Therefore, an urgent need exists for prospective research protocols that study the risk versus benefit of using organs for hepatitis C–infected donors. In response to this rapidly changing practice and the need for scientific study and consensus, the American Society of Transplantation convened a meeting of experts to review current data and develop the framework for the study of using HCV viremic organs in solid organ transplantation.

AB - The availability of direct-acting antiviral agents for the treatment of hepatitis C virus (HCV) infection has resulted in a profound shift in the approach to the management of this infection. These changes have affected the practice of solid organ transplantation by altering the framework by which patients with end-stage organ disease are managed and receive organ transplants. The high level of safety and efficacy of these medications in patients with chronic HCV infection provides the opportunity to explore their use in the setting of transplanting organs from HCV-viremic patients into non–HCV-viremic recipients. Because these organs are frequently discarded and typically come from younger donors, this approach has the potential to save lives on the solid organ transplant waitlist. Therefore, an urgent need exists for prospective research protocols that study the risk versus benefit of using organs for hepatitis C–infected donors. In response to this rapidly changing practice and the need for scientific study and consensus, the American Society of Transplantation convened a meeting of experts to review current data and develop the framework for the study of using HCV viremic organs in solid organ transplantation.

KW - clinical decision-making

KW - clinical research/practice

KW - clinical trial design

KW - donors and donation: donor-derived infections

KW - education

KW - infection and infectious agents

KW - organ allocation

KW - organ procurement and allocation

KW - organ transplantation in general

KW - viral: hepatitis C

UR - http://www.scopus.com/inward/record.url?scp=85021665485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021665485&partnerID=8YFLogxK

U2 - 10.1111/ajt.14381

DO - 10.1111/ajt.14381

M3 - Article

C2 - 28556422

AN - SCOPUS:85021665485

SN - 1600-6135

VL - 17

SP - 2790

EP - 2802

JO - American Journal of Transplantation

JF - American Journal of Transplantation

IS - 11

ER -

The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this